These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Tumoricidal properties of rat peritoneal macrophages activated with various activators depend on nitrogen oxid synthesis. Kusenda J; Kalafut F; Klobusická M; Novotná L Neoplasma; 1992; 39(1):15-21. PubMed ID: 1528300 [TBL] [Abstract][Full Text] [Related]
23. Dissection of antigenic and irritative effects of epicutaneously applied haptens in mice. Evidence that not the antigenic component but nonspecific proinflammatory effects of haptens determine the concentration-dependent elicitation of allergic contact dermatitis. Grabbe S; Steinert M; Mahnke K; Schwartz A; Luger TA; Schwarz T J Clin Invest; 1996 Sep; 98(5):1158-64. PubMed ID: 8787679 [TBL] [Abstract][Full Text] [Related]
24. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316 [TBL] [Abstract][Full Text] [Related]
25. The definitive value of active-specific immunotherapy for experimental carcinoma of the colon. Enker WE; Jacobitz JL Surgery; 1976 Aug; 80(2):164-70. PubMed ID: 941090 [TBL] [Abstract][Full Text] [Related]
26. Use of a synthetic hapten in the demonstration of the Thomsen-Friedenreich (T) antigen on neuraminidase-treated human red blood cells and lymphocytes. Bray J; Lemieux RU; McPherson TA J Immunol; 1981 May; 126(5):1966-9. PubMed ID: 7217675 [TBL] [Abstract][Full Text] [Related]
28. Effect of passively administered isologous anti-idiotypes directed against anti-carrier (ovalbumin) antibodies on the anti-hapten IgE and IgG antibody responses in BALB/c mice. Blaser K; Nakagawa T; De Weck AL Immunology; 1983 Mar; 48(3):423-31. PubMed ID: 6600704 [TBL] [Abstract][Full Text] [Related]
29. Analysis of true anti-hapten cytotoxic clones in limit dilution microcultures after correction for "anti-self" activity: precursor frequencies, Ly-2 and Thy-1 phenotype, specificity, and statistical methods. Good MF; Boyd AW; Nossal GJ J Immunol; 1983 May; 130(5):2046-55. PubMed ID: 6187833 [TBL] [Abstract][Full Text] [Related]
30. [Suicidal cancer vaccine enhances anti-tumor immunotherapeutic effect and its safety in the treatment of ovarian cancer]. Kang Y; Xu CJ; Liu XS; Shao ZM; Ou ZL; Luo JM; Wu CQ; Zhong CP; Gu JR Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):654-7. PubMed ID: 17274368 [TBL] [Abstract][Full Text] [Related]
31. [The augmentation of tumor-specific immunity by T-T cell interaction]. Fujiwara H; Takai Y; Fukuzawa M; Yoshioka T; Izumi Y; Mizushima Y; Qian J; Ogata M; Kosugi A; Nakajima H Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 2):734-40. PubMed ID: 3157349 [TBL] [Abstract][Full Text] [Related]
32. Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody. Gautherot E; Kraeber-Bodéré F; Daniel L; Fiche M; Rouvier E; Saï-Maurel C; Thedrez P; Chatal JF; Barbet J Clin Cancer Res; 1999 Oct; 5(10 Suppl):3177s-3182s. PubMed ID: 10541361 [TBL] [Abstract][Full Text] [Related]
33. Hapten-specific murine colony-forming B cells: in vitro response of colonies to fluoresceinated thymus independent antigens. Pillai PS; Scott DW J Immunol; 1981 May; 126(5):1883-6. PubMed ID: 6163821 [TBL] [Abstract][Full Text] [Related]
34. The specificity of in vivo tolerance to haptens in NZB and normal mice after exposure to hapten-modified syngeneic spleen cells. Cowdery JS; Laskin CA; Steinberg AD J Immunol; 1982 Apr; 128(4):1571-6. PubMed ID: 6174607 [TBL] [Abstract][Full Text] [Related]
35. Neutralization of IL-12 in vivo prevents induction of contact hypersensitivity and induces hapten-specific tolerance. Riemann H; Schwarz A; Grabbe S; Aragane Y; Luger TA; Wysocka M; Kubin M; Trinchieri G; Schwarz T J Immunol; 1996 Mar; 156(5):1799-803. PubMed ID: 8596029 [TBL] [Abstract][Full Text] [Related]
36. Thermally-enhanced tumor regression in mice treated with melphalan. Goldfeder A; Neubort S Anticancer Res; 1984; 4(1-2):17-22. PubMed ID: 6712172 [TBL] [Abstract][Full Text] [Related]
37. Regression of untreated tumor following immunotherapy of primary tumor in rats. Arai K; Wallace HW; Blakemore WS Surg Forum; 1973; 24():117-8. PubMed ID: 4805961 [No Abstract] [Full Text] [Related]
38. Effect of anti-hapten serum on hapten-treated rat tumor. Wallace HW; Arai K Surg Forum; 1978; 29():126-8. PubMed ID: 401112 [No Abstract] [Full Text] [Related]
39. Effect of local immunotherapy of syngeneic rat fibrosarcoma with hapten and antihapten-tumor serum upon nonlocally treated tumor. Arai K; Wallace HW Cancer Res; 1979 Sep; 39(9):3638-43. PubMed ID: 314334 [No Abstract] [Full Text] [Related]
40. Effect of hapten plus antihapten-tumor serum treatment on established rat fibrosarcoma. Arai K; Spencer JS; Sohn M; Wallace HW Cancer Res; 1979 Jan; 39(1):6-16. PubMed ID: 310708 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]